Skip to Content

Shattuck Labs Inc Ordinary Shares STTK

Morningstar Rating
$8.94 −0.04 (0.45%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

STTK is trading at a 62% discount.
Price
$9.13
Fair Value
$41.43
Uncertainty
Extreme
1-Star Price
$411.73
5-Star Price
$3.23
Economic Moat
Tslwj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STTK is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$8.98
Day Range
$8.689.03
52-Week Range
$1.3311.11
Bid/Ask
$8.67 / $9.82
Market Cap
$424.42 Mil
Volume/Avg
319,072 / 420,468

Key Statistics

Price/Earnings (Normalized)
Price/Sales
229.84
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
75

Comparables

Valuation

Metric
STTK
CLDX
TYRA
Price/Earnings (Normalized)
Price/Book Value
2.925.473.45
Price/Sales
229.84295.42
Price/Cash Flow
Price/Earnings
STTK
CLDX
TYRA

Financial Strength

Metric
STTK
CLDX
TYRA
Quick Ratio
11.4113.6913.27
Current Ratio
12.5113.8713.80
Interest Coverage
Quick Ratio
STTK
CLDX
TYRA

Profitability

Metric
STTK
CLDX
TYRA
Return on Assets (Normalized)
−48.33%−30.49%−22.50%
Return on Equity (Normalized)
−54.85%−33.19%−23.73%
Return on Invested Capital (Normalized)
−56.35%−32.85%−27.79%
Return on Assets
STTK
CLDX
TYRA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQkpwtqtbhcWgbnc$570.1 Bil
VRTX
Vertex Pharmaceuticals IncZxxvdcfzDqpbvq$108.0 Bil
REGN
Regeneron Pharmaceuticals IncDyrszgvnRcwyp$105.6 Bil
MRNA
Moderna IncLqbsqyccZbf$40.8 Bil
ARGX
argenx SE ADRPxvtnjfwJpx$23.5 Bil
BNTX
BioNTech SE ADRVbrwtcbffShx$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncRxrwnbdSzqsxqb$18.8 Bil
BMRN
Biomarin Pharmaceutical IncVrcflnhsTjsqjg$16.5 Bil
RPRX
Royalty Pharma PLC Class ALbvbdljlCxhzkw$13.6 Bil
INCY
Incyte CorpHtdpbjjxxJgcwz$12.8 Bil

Sponsor Center